MiR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 334-341

  Favreau, Amanda J ^a,b   Sathyanarayana, Pradeep ^a  

^a Maine Medical Center Research Institute   (United States)

^b UNIVERSITY OF MAINE   (United States)

Author keywords

AML; AML 193; G CSF; GM CSF; IL 3; MiRNA

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; JANUS KINASE 2; MICRORNA; MICRORNA 15B; MICRORNA 219 5P; MICRORNA 590 5P; MICRORNA 628 5P; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL STIMULATION; CELL STRAIN AML 193; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84855915298     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.027     Document Type: Article

References (62)

1. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
2. Spivak J.L., Smith R.R., Ihle J.N. Interleukin 3 promotes the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest 1985, 76:1613-1621.
3. Broxmeyer H.E., Williams D.E. The production of myeloid blood cells and their regulation during health and disease. Crit Rev Oncol Hematol 1988, 8:173-226.
4. Broxmeyer H.E., Williams D.E., Hangoc G., et al. Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony-stimulating factor 1, recombinant murine interleukin 3, and recombinant murine granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A 1987, 84:3871-3875.
5. Feldman G.M., Rosenthal L.A., Liu X., et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 1997, 90:1768-1776.
6. Mui A.L., Wakao H., Harada N., O'Farrell A.M., Miyajima A. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol 1995, 57:799-803.
7. Rosen R.L., Winestock K.D., Chen G., Liu X., Hennighausen L., Finbloom D.S. Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes. Blood 1996, 88:1206-1214.
8. Tian S.S., Tapley P., Sincich C., Stein R.B., Rosen J., Lamb P. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 1996, 88:4435-4444.
9. Lange B., Valtieri M., Santoli D., et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987, 70:192-199.
10. Valtieri M., Boccoli G., Testa U., Barletta C., Peschle C. Two-step differentiation of AML-193 leukemic line: terminal maturation is induced by positive interaction of retinoic acid with granulocyte colony-stimulating factor (CSF) and vitamin D3 with monocyte CSF. Blood 1991, 77:1804-1812.
11. Tsubokawa M., Tohyama Y., Tohyama K., et al. Interleukin-3 activates Syk in a human myeloblastic leukemia cell linem, AML193. Eur J Biochem 1997, 249:792-796.
12. Du X., Ho M., Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007, 30:607-613.
13. Brasel K., Escobar S., Anderberg R., de Vries P., Gruss H.J., Lyman S.D. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995, 9:1212-1218.
14. Lyman S.D., Jacobsen S.E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91:1101-1134.
15. Carow C.E., Levenstein M., Kaufmann S.H., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996, 87:1089-1096.
16. Sitnicka E., Buza-Vidas N., Larsson S., Nygren J.M., Liuba K., Jacobsen S.E. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003, 102:881-886.
17. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
18. O'Connell R.M., Chaudhuri A.A., Rao D.S., Gibson W.S., Balazs A.B., Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A 2010, 107:14235-14240.
19. Kuchen S., Resch W., Yamane A., et al. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 2010, 32:828-839.
20. Ooi A.G., Sahoo D., Adorno M., Wang Y., Weissman I.L., Park C.Y. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A 2010.
21. Fazi F., Rosa A., Fatica A., et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005, 123:819-831.
22. Pulikkan J.A., Dengler V., Peramangalam P.S., et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010, 115:1768-1778.
23. Garzon R., Pichiorri F., Palumbo T., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
24. Careccia S., Mainardi S., Pelosi A., et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 2009, 28:4034-4040.
25. Calin G.A., Cimmino A., Fabbri M., et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008, 105:5166-5171.
26. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
27. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
28. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
29. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu Rev Med 2009, 60:167-179.
30. Calin G.A., Sevignani C., Dumitru C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
31. Testa U., Riccioni R., Militi S., et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002, 100:2980-2988.
32. Marvin J., Swaminathan S., Kraker G., Chadburn A., Jacobberger J., Goolsby C. Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 2011, 117:e120-e130.
33. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999, 18:4754-4765.
34. Matsumoto A., Masuhara M., Mitsui K., et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997, 89:3148-3154.
35. Lehtonen A., Matikainen S., Miettinen M., Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol 2002, 71:511-519.
36. Ferbeyre G, Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta;1815:104-14.
37. Johnson S.M., Grosshans H., Shingara J., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
38. Lee Y.S., Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025-1030.
39. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
40. Pons A., Nomdedeu B., Navarro A., et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009, 50:1854-1859.
41. Garzon R., Garofalo M., Martelli M.P., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-3950.
42. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
43. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
44. Andrieux J., Roche-Lestienne C., Geffroy S., et al. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genet Cytogenet 2007, 178:11-16.
45. Owens P., Pickup M.W., Novitskiy S.V., et al. Breast cancer special feature: disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci U S A 2011.
46. Liu X.L., Yuan J.Y., Zhang J.W., Zhang X.H., Wang R.X. Differential gene expression in human hematopoietic stem cells specified toward erythroid, megakaryocytic, and granulocytic lineage. J Leukoc Biol 2007, 82:986-1002.
47. Waggoner S.A., Johannes G.J., Liebhaber S.A. Depletion of the poly(C)-binding proteins alphaCP1 and alphaCP2 from K562 cells leads to p53-independent induction of cyclin-dependent kinase inhibitor (CDKN1A) and G1 arrest. J Biol Chem 2009, 284:9039-9049.
48. Blank U., Karlsson S. The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 2011.
49. Wang N., Kim H.-G., Cotta C.V., et al. TGF[beta]/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability. EMBO J 2006, 25:1469-1480.
50. Quere R., Karlsson G., Hertwig F., et al. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood 2011, 117:5918-5930.
51. Liebermann D.A., Hoffman B. Myeloid differentiation (MyD) primary response genes in hematopoiesis. Blood Cells Mol Dis 2003, 31:213-228.
52. Gupta S.K., Gupta M., Hoffman B., Liebermann D.A. Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation. Oncogene 2006, 25:5537-5546.
53. Hoffman B., Liebermann D.A. Gadd45 modulation of intrinsic and extrinsic stress responses in myeloid cells. J Cell Physiol 2009, 218:26-31.
54. Griffiths E.A., Gore S.D., Hooker C., et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma 2010, 51:1711-1719.
55. Wang Y., Krivtsov A.V., Sinha A.U., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
56. Li G., Miskimen K.L., Wang Z., et al. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 2010, 115:1416-1424.
57. Ofir M., Hacohen D., Ginsberg D. miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 2011, 9:440-447.
58. Bonci D., Coppola V., Musumeci M., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
59. Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 1998, 47:187-199.
60. Santamaria C.M., Chillon M.C., Garcia-Sanz R., et al. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res 2009, 33:1706-1709.
61. Kornblau S.M., Singh N., Qiu Y., Chen W., Zhang N., Coombes K.R. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010, 16:1865-1874.
62. Nelson E.A., Walker S.R., Weisberg E., et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117:3421-3429.